Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced HER2 Negative Breast Cancer
28 juin 2021 01h00 HE
|
Polyphor AG
Co-primary endpoint of the study objective response rate (ORR) was not metThe board of directors is undergoing a strategic assessment regarding the future of the company ALLSCHWIL, Switzerland,...
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist
08 juin 2021 01h30 HE
|
Polyphor AG
ALLSCHWIL, Switzerland, June 08, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing...
Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials
01 juin 2021 01h30 HE
|
Polyphor AG
Balixafortide showed a clear anti-viral effect, different from remdesivir, in a 14-day laboratory (CPE) assay Balixafortide single agent treatment showed statistically significant reduction of viral...
Polyphor to Present at the UBS Global Healthcare Virtual Conference
18 mai 2021 01h30 HE
|
Polyphor AG
ALLSCHWIL, Switzerland, May 18, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing...
Polyphor Announces Financial Results for the Full-Year 2020
05 mars 2021 01h15 HE
|
Polyphor AG
Phase III trial patient enrollment for balixafortide completed in Q4 2020 despite COVID-19. Results expected for ORR and PFS in Q2 and Q4 2021 respectivelyExclusive licensing agreement for...
Polyphor to Present Full-Year 2020 Financial Results on March 5
26 févr. 2021 01h30 HE
|
Polyphor AG
ALLSCHWIL, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) announced today that it will publish its full-year financial results for 2020 on March 5 at 7:30am CET. Gökhan...
Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
05 janv. 2021 01h30 HE
|
Polyphor AG
ALLSCHWIL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci...
Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
22 déc. 2020 01h30 HE
|
Polyphor AG
Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by...
Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Phase III balixafortide FORTRESS Study Without Modifications
14 déc. 2020 01h30 HE
|
Polyphor AG
ALLSCHWIL, Switzerland, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) announced today that the clinical trial independent Data Safety Monitoring Board (DSMB) has completed the third,...
Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of a New Class of Antibiotics Targeting Multi-Drug Resistant Gram-Negative Pathogens
11 déc. 2020 01h30 HE
|
Polyphor AG
ALLSCHWIL, Switzerland, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announced the extension of its existing grant agreement with CARB-X (Combating Antibiotic-Resistant Bacteria...